Day: April 20, 2016

Clarifying what the TPP IP provisions mean in Canada for the Innovative Life Sciences SectorClarifying what the TPP IP provisions mean in Canada for the Innovative Life Sciences Sector



This is a guest blog post by Declan Hamill, Chief of Staff and Vice President, Legal Affairs, Innovative Medicines Canada.

Innovative Medicines Canada is the association of leading innovative pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development (R&D) each year to fuel Canada’s knowledge-based economy, contributing over $3 billion to the Canadian economy.